Blockade of STAT3 in T Cells Inhibits Germinal Center Reactions against Intranasal Allergens.
10.4062/biomolther.2015.160
- Author:
Garam CHOI
1
;
Yeonseok CHUNG
Author Information
1. Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea. yeonseok@snu.ac.kr
- Publication Type:Original Article
- Keywords:
STAT3;
Intranasal allergens;
Tfh cell;
Germinal center reactions;
Immunoglobulin
- MeSH:
Allergens*;
B-Lymphocytes;
Germinal Center*;
Immunity, Humoral;
Immunoglobulin E;
Immunoglobulin G;
Immunoglobulins;
Lung;
Lymph Nodes;
Pathology;
Pneumonia;
T-Lymphocytes*
- From:Biomolecules & Therapeutics
2016;24(3):244-251
- CountryRepublic of Korea
- Language:English
-
Abstract:
Understanding the developmental mechanisms of humoral immunity against intranasal antigens is essential for the development of therapeutic approaches against air-borne pathogens as well as allergen-induced pulmonary inflammation. Follicular helper T (Tfh) cells expressing CXCR5 are required for humoral immunity by providing IL-21 and ICOS costimulation to activated B cells. However, the regulation of Tfh cell responses against intranasal antigens remains unclear. Here, we found that the generation of Tfh cells and germinal center B cells in the bronchial lymph node against intranasal proteinase antigens was independent of TGF-β. In contrast, administration of STAT3 inhibitor STA-21 suppressed the generation of Tfh cells and germinal center B cells. Compared with wild-type OT-II T cells, STAT3-deficient OT-II T cells transferred into recipients lacking T cells not only showed significantly reduced frequency Tfh cells, but also induced diminished IgG as well as IgE specific for the intranasal antigens. Co-transfer study of wild-type OT-II and STAT3-deficient OT-II T cells revealed that the latter failed to differentiate into Tfh cells. These findings demonstrate that T cell-intrinsic STAT3 is required for the generation of Tfh cells to intranasal antigens and that targeting STAT3 might be an effective approach to ameliorate antibody-mediated pathology in the lung.
